Protocol for a randomized controlled trial to evaluate a permissive blood pressure target versus usual care in critically ill children with hypotension (PRESSURE)
Author(s)
Type
Journal Article
Abstract
OBJECTIVES:
Management of hypotension is a fundamental part of pediatric critical care, with cardiovascular support in the form of fluids or vasoactive drugs offered to every hypotensive child. However, optimal blood pressure (BP) targets are unknown. The PRotocolised Evaluation of PermiSSive BP Targets Versus Usual CaRE (PRESSURE) trial aims to evaluate the clinical and cost-effectiveness of a permissive mean arterial pressure (MAP) target of greater than a fifth centile for age compared with usual care.
DESIGN:
Pragmatic, open, multicenter, parallel-group randomized control trial (RCT) with integrated economic evaluation.
SETTING:
Eighteen PICUs across the United Kingdom.
PATIENTS:
Infants and children older than 37 weeks corrected gestational age to 16 years accepted to a participating PICU, on mechanical ventilation and receiving vasoactive drugs for hypotension.
INTERVENTIONS:
Adjustment of hemodynamic support to achieve a permissive MAP target greater than fifth centile for age during invasive mechanical ventilation.
MEASUREMENTS AND MAIN RESULTS:
Randomization is 1:1 to a permissive MAP target or usual care, stratified by site and age group. Due to the emergency nature of the treatment, approaching patients for written informed consent will be deferred until after randomization. The primary clinical outcome is a composite of death and days of ventilatory support at 30 days. Baseline demographics and clinical status will be recorded as well as daily measures of BP and organ support, and discharge outcomes. This RCT received Health Research Authority approval (reference 289545), and a favorable ethical opinion from the East of England—Cambridge South Research Ethics Committee on May 10, 2021 (reference number 21/EE/0084). The trial is registered and has an International Standard RCT Number (reference 20609635).
CONCLUSIONS:
Trial findings will be disseminated in U.K. national and international conferences and in peer-reviewed journals.
Management of hypotension is a fundamental part of pediatric critical care, with cardiovascular support in the form of fluids or vasoactive drugs offered to every hypotensive child. However, optimal blood pressure (BP) targets are unknown. The PRotocolised Evaluation of PermiSSive BP Targets Versus Usual CaRE (PRESSURE) trial aims to evaluate the clinical and cost-effectiveness of a permissive mean arterial pressure (MAP) target of greater than a fifth centile for age compared with usual care.
DESIGN:
Pragmatic, open, multicenter, parallel-group randomized control trial (RCT) with integrated economic evaluation.
SETTING:
Eighteen PICUs across the United Kingdom.
PATIENTS:
Infants and children older than 37 weeks corrected gestational age to 16 years accepted to a participating PICU, on mechanical ventilation and receiving vasoactive drugs for hypotension.
INTERVENTIONS:
Adjustment of hemodynamic support to achieve a permissive MAP target greater than fifth centile for age during invasive mechanical ventilation.
MEASUREMENTS AND MAIN RESULTS:
Randomization is 1:1 to a permissive MAP target or usual care, stratified by site and age group. Due to the emergency nature of the treatment, approaching patients for written informed consent will be deferred until after randomization. The primary clinical outcome is a composite of death and days of ventilatory support at 30 days. Baseline demographics and clinical status will be recorded as well as daily measures of BP and organ support, and discharge outcomes. This RCT received Health Research Authority approval (reference 289545), and a favorable ethical opinion from the East of England—Cambridge South Research Ethics Committee on May 10, 2021 (reference number 21/EE/0084). The trial is registered and has an International Standard RCT Number (reference 20609635).
CONCLUSIONS:
Trial findings will be disseminated in U.K. national and international conferences and in peer-reviewed journals.
Date Issued
2024-07-01
Date Acceptance
2024-06-01
Citation
Pediatric Critical Care Medicine, 2024, 25 (7), pp.629-637
ISSN
1529-7535
Publisher
Lippincott, Williams & Wilkins
Start Page
629
End Page
637
Journal / Book Title
Pediatric Critical Care Medicine
Volume
25
Issue
7
Copyright Statement
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/38629915
PII: 00130478-202407000-00007
Subjects
ASSOCIATION
Critical Care Medicine
DEATH
General & Internal Medicine
HEALTHY
inotrope
INTENSIVE-CARE
Life Sciences & Biomedicine
mean arterial pressure
MORTALITY
OUTCOMES
pediatric intensive care
Pediatrics
PERFORMANCE
QUALITY-OF-LIFE
randomized clinical trial
Science & Technology
SEPSIS
vasopressor
VASOPRESSOR THERAPY
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2024-07-01